| RE50313 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | Mar 02, 22 | Feb 25, 25 | CELLATOZ THERAPEUTICS, INC. |
| RE50283 | Effective delivery of large genes by dual AAV vectors | Dec 03, 21 | Jan 28, 25 | FONDAZIONE TELETHON ETS |
| RE50240 | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier | Jan 29, 21 | Dec 24, 24 | JCR Pharmaceuticals Co. Ltd. |
| RE50241 | Electroporation apparatus having an elongated hollow member | Jul 13, 23 | Dec 24, 24 | Life Technologies Holdings PTE LTD |
| RE50172 | In vitro maturation of a mammalian cumulus oocyte complex | Aug 27, 21 | Oct 15, 24 | Vrije Universiteit Brussel |
| RE49967 | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase | May 27, 21 | May 14, 24 | Takeda Pharmaceutical Company Limited |
| RE49936 | Beta-hexosyl-transferases and uses thereof | Dec 18, 20 | Apr 23, 24 | North Carolina State University |
| RE49736 | Pegylated L-asparaginase | Mar 18, 20 | Nov 28, 23 | Jazz Pharmaceuticals II SAS |
| RE49708 | Nucleic acid molecules encoding indoleamine 2,3-dioxygenase-2 | Jan 08, 21 | Oct 24, 23 | Lankenau Institute for Medical Research |
| RE49583 | Inducible expression systems | Feb 03, 21 | Jul 18, 23 | TET Systems GmbH & Co. KG |
| RE49431 | RNA interference agents for GST-PI gene modulation | Aug 11, 20 | Feb 28, 23 | Nitto Denko Corporation |
| RE49423 | DNA plasmids with improved expression | Dec 04, 20 | Feb 21, 23 | Nature Technology Corporation |
| RE49347 | Mammalian expression vector | Aug 23, 18 | Dec 27, 22 | Novartis AG |
| RE49311 | RTI545 compositions and methods of use for benefiting plant growth and controlling plant pests | Jan 22, 20 | Nov 29, 22 | FMC Corporation |
| RE49293 | Cell culture methods and devices utilizing gas permeable materials | Jun 12, 18 | Nov 15, 22 | Wilson Wolf Manufacturing Corporation |
| RE49294 | DNA vector production system | Mar 05, 20 | Nov 15, 22 | Mediphage Bioceuticals, Inc. |
| RE49280 | TGFbeta type II-type III receptor fusions | Apr 04, 19 | Nov 08, 22 | 501 Board of Regents The University of Texas System |
| RE49281 | Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factors | Dec 13, 19 | Nov 08, 22 | Whitehead Institute for Biomedical Research |
| RE49233 | Ionizable cationic lipid for RNA delivery | Mar 12, 19 | Oct 04, 22 | Arcturus Therapeutics, Inc. |
| RE49229 | Methods and compositions for treating malignant tumors associated with KRAS mutation | Feb 28, 20 | Oct 04, 22 | Nitto Denko Corporation |